Strategic Patenting in Biotechnology

The patent management trichotomy: patenting, publishing, and secrecy

“…Technology exclusivity, in turn, can be protected by patents or trade secrets (Arundel, 2001, Granstrand, 1999. Numerous studies have found that the protection of innovations and prevention of imitation is the main motive for patenting (Arundel et al, 1995, Blind et al, 2006, Cohen et al, 2000, Duguet and Kabla, 1998, Giuri et al, 2007, Granstrand, 1999, Thumm, 2004a, Veer and Jell, 2012, Thumm, 2004b. Publishing is not associated with such benefits, while secrecy is (Arundel, 2001, Hannah, 2005.…”

When technological discontinuities and disruptive business models challenge dominant industry logics: Insights from the drugs industry

“…As the supposed 3 cost of drug discovery, development and commercialization can exceed US$1Bn, and take ten to fifteen years to achieve (DiMasi and Grabowski, 2007;DiMasi et al, 2003), intellectual property rights are used throughout the drug industry to protect discoveries, technologies and products (Thumm, 2004), and its keenness to defend and maintain the high returns from its IP rights -even when this stance is unfavorable to the needs of developing countries -has led to much criticism of the industry (De George, 2005;McGoey et al, 2011). Recent studies report both the general stability of IP rights in the drug industry (Lilico, 2006), but also that company's policies with regard to those rights are slowly evolving (Allarakhia and Walsh, 2011).…”

Investigating the determinants of patent acquisition in biotechnology: an empirical analysis

“…OECD data (2013), in fact, report 19,151 biotechnology firms active in 2013 and an industry Downloaded by [University of Nebraska, Lincoln] at 23:37 05 April 2015 R&D expenditure of 41,219 million of US dollars. Biotechnology is a knowledge-based industry (Alegre, Chiva, and Lapiedra 2009;McMillan, Narin, and Deeds 2000;Messeni Petruzzelli, Rotolo, and Albino 2012), having a high rate of innovation development (Sørensen and Stuart 2000), where patents play a major strategic role both in protecting and commercialising new knowledge (Thumm 2004;Zucker, Darby, and Armstrong 2002). Additionally, in biotechnology there is a higher propensity to trade patent rights than in other industries (Anand and Khanna 2000).…”

“…In addition, we controlled for firm's subsidiary status (Phene and Almeida 2008) by a dummy variable (Subsidiary), taking value one if the firm is a subsidiary and zero otherwise. Additionally, under some circumstances, organisations may decide to acquire patents for various strategic purposes (Reitzig 2004;Thumm 2004). In order to control for the purpose of acquiring patents to be expansion of scientific or technological knowledge, we added a variable (TechRelated) indicating the extent to which the acquired patent is related to the buying firm's patent portfolio.…”